Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma.


Journal

Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060

Informations de publication

Date de publication:
Jun 2022
Historique:
received: 03 05 2021
accepted: 12 07 2021
pubmed: 21 7 2021
medline: 20 5 2022
entrez: 20 7 2021
Statut: ppublish

Résumé

MDRO-colonization has been shown to impair survival in patients with hematological malignancies and solid tumors as well as in patients with liver disease. Despite the increasing spread of multidrug-resistant organisms (MDRO), its impact on patients with hepatocellular carcinoma (HCC) has not been studied. We conducted this retrospective study to analyze the impact of MDRO-colonization on overall prognosis in HCC patients. All patients with confirmed HCC diagnosed between January 2008 and December 2017 at the University Hospital Frankfurt were included in this study. HCC patients with a positive MDRO screening before or within the first 90 days after diagnosis of HCC were defined as colonized HCC patients, HCC patients with a negative MDRO screening were defined as noncolonized HCC patients. 59 (6%) colonized and 895 (94%) noncolonized HCC patients were included. Enterobacterales with extended-spectrum β-lactamase-like phenotype with or without resistance to fluoroquinolones (ESBL/ ± FQ) were the most frequently found MDRO with 59%, followed by vancomycin-resistant Enterococcus faecium with 37%. Colonized HCC patients had more severe cirrhosis and more advanced HCC stage compared to noncolonized HCC patients. Colonized HCC patients showed an impaired survival with a median OS of 189 days (6.3 months) compared to a median OS of 1001 days (33.4 months) in noncolonized HCC patients. MDRO-colonization was identified as an independent risk factor associated with survival in multivariate analysis. MDRO-colonization is an independent risk factor for survival in patients with HCC highlighting the importance of regular MDRO screening, isolation measures as well as interdisciplinary antibiotic steward-ship programs to guide responsible use of antibiotic agents.

Identifiants

pubmed: 34283288
doi: 10.1007/s00432-021-03741-0
pii: 10.1007/s00432-021-03741-0
pmc: PMC9114096
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1465-1472

Informations de copyright

© 2021. The Author(s).

Références

PLoS One. 2019 Jan 23;14(1):e0210991
pubmed: 30673776
N Engl J Med. 2020 May 28;382(22):2137-2145
pubmed: 32459924
Lancet Infect Dis. 2017 Sep;17(9):990-1001
pubmed: 28629876
Gut. 2015 Jul;64(7):1183-4
pubmed: 25616276
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
J Am Med Dir Assoc. 2012 Jul;13(6):568.e1-13
pubmed: 22575772
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
PLoS One. 2015 May 21;10(5):e0127448
pubmed: 25996499
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Gastroenterology. 2010 Oct;139(4):1246-56, 1256.e1-5
pubmed: 20558165
Euro Surveill. 2016;21(2):
pubmed: 26794850
Ann N Y Acad Sci. 2014 Sep;1323:22-42
pubmed: 25195939
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Oct;55(10):1311-54
pubmed: 23011096
Hepatology. 2001 Feb;33(2):464-70
pubmed: 11172350
PLoS One. 2020 Nov 25;15(11):e0242544
pubmed: 33237921
BMC Infect Dis. 2017 Jan 5;17(1):17
pubmed: 28056820
J Hepatol. 2016 Nov;65(5):1043-1054
pubmed: 27544545
Liver Int. 2017 Oct;37(10):1488-1496
pubmed: 28374901
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
PLoS One. 2021 Jan 22;16(1):e0245091
pubmed: 33481811
J Antimicrob Chemother. 2014 Jun;69(6):1660-4
pubmed: 24615816
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
Dig Dis Sci. 2007 Nov;52(11):3285-9
pubmed: 17436087
Hepatology. 2016 Jun;63(6):2019-31
pubmed: 26528864

Auteurs

Vera Himmelsbach (V)

Department of Medicine, Gastroenterology, Hepatology and Endocrinology, Goethe University Frankfurt, Frankfurt/Main, Germany.

Mate Knabe (M)

Department of Medicine, Gastroenterology, Hepatology and Endocrinology, Goethe University Frankfurt, Frankfurt/Main, Germany.

Phillip G Ferstl (PG)

Department of Medicine, Gastroenterology, Hepatology and Endocrinology, Goethe University Frankfurt, Frankfurt/Main, Germany.

Kai-Henrik Peiffer (KH)

Department of Medicine, Gastroenterology, Hepatology and Endocrinology, Goethe University Frankfurt, Frankfurt/Main, Germany.

Jan A Stratmann (JA)

University Cancer Center, Goethe University Hospital, Frankfurt/Main, Germany.
Department of Medicine, Hematology/Oncology, Goethe University Hospital, Frankfurt/Main, Germany.

Thomas A Wichelhaus (TA)

Institute of Medical Microbiology and Infection Control, Goethe University Hospital, Frankfurt/Main, Germany.
University Center of Competence for Infection Control of the State of Hesse, Frankfurt/Main, Germany.

Michael Hogardt (M)

Institute of Medical Microbiology and Infection Control, Goethe University Hospital, Frankfurt/Main, Germany.
University Center of Competence for Infection Control of the State of Hesse, Frankfurt/Main, Germany.

Volkhard A J Kempf (VAJ)

Institute of Medical Microbiology and Infection Control, Goethe University Hospital, Frankfurt/Main, Germany.
University Center of Competence for Infection Control of the State of Hesse, Frankfurt/Main, Germany.

Stefan Zeuzem (S)

Department of Medicine, Gastroenterology, Hepatology and Endocrinology, Goethe University Frankfurt, Frankfurt/Main, Germany.

Oliver Waidmann (O)

Department of Medicine, Gastroenterology, Hepatology and Endocrinology, Goethe University Frankfurt, Frankfurt/Main, Germany.
University Cancer Center, Goethe University Hospital, Frankfurt/Main, Germany.

Fabian Finkelmeier (F)

Department of Medicine, Gastroenterology, Hepatology and Endocrinology, Goethe University Frankfurt, Frankfurt/Main, Germany.
University Cancer Center, Goethe University Hospital, Frankfurt/Main, Germany.

Olivier Ballo (O)

Department of Medicine, Gastroenterology, Hepatology and Endocrinology, Goethe University Frankfurt, Frankfurt/Main, Germany. olivier.ballo@kgu.de.
University Cancer Center, Goethe University Hospital, Frankfurt/Main, Germany. olivier.ballo@kgu.de.
Department of Medicine, Hematology/Oncology, Goethe University Hospital, Frankfurt/Main, Germany. olivier.ballo@kgu.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH